Table 1 Comparison of clinical data between the groups of initial IVIG-response and IVIG-resistance in KD

Male

403(56.9)

59(51.3)

0.267

Age, years

2.1(1.2–3.6)

2.3(1.3–4.5)

0.026

Clinical manifestations

Rash

549(77.5)

96(83.5)

0.190

Extremity changes

393(55.5)

65(57.4)

0.762

Conjunctivitis

651(91.9)

103(89.6)

0.368

Oral changes

639(90.3)

108(93.9)

0.296

Cervical lymphadenopathy

310(43.8)

62(53.9)

0.055

Fever duration before initial IVIG, days

5.0(5.0–6.0)

5.0(4.0–6.0)

0.212

Incomplete KD

275(38.8)

36(31.3)

0.146

CALs in the acute phase of KD

71(10.0)

15(13.0)

0.325

Before initial IVIG

Time of blood test from fever onset, days

5.0(4.0–6.0)

4.0(3.0–5.0)

0.558

WBC, ×10⁹/L

13.2(10.7–16.6)

13.6(10.0-16.9)

0.515

Neutrophil, %

66.2(77.0–56.0)

77.5(66.2–84.0)

<0.001

Lymphocyte, %

24.6(16.0–33.0)

15.0(9.6–24.0)

<0.001

Hemoglobin, g/L

109(102–117)

107(101–114)

0.036

PLT, ×10⁹/L

316(259–387)

290(196–348)

<0.001

CRP, mg/L

71.0(43.0-107.0)

92.1(62.0-144.0)

<0.001

ESR, mm/h

64.0(46.0–81.0)

67.0(48.0–87.0)

0.152

AST, U/L

33.0(25.0–49.0)

37.0(25.0–73.0)

0.161

ALT, U/L

36.0(20.0-77.7)

54.0(27.0-125.0)

0.006

ALB, g/L

38.0(35.0–41.0)

36.0(30.3–39.0)

0.004

TBil, µmol/L

6.0(4.0-8.5)

7.0(5.0–19.0)

<0.001

Na⁺, mmol/L

137.0(135.0-139.0)

135.0(133.0-137.0)

<0.001

ALBI

–2.73(–3.00- (–2.46))

–2.38(–2.69- (–1.93))

<0.001